Clodronate Improves Bone Density in Post-Menopausal Breast Cancer Patients
Author Information
Author(s): T Saarto, C Blomqvist, M Valimaki, P Makela, S Sarna, I Elomaa
Primary Institution: Helsinki University Central Hospital
Hypothesis
Does clodronate improve bone mineral density in post-menopausal breast cancer patients treated with antioestrogens?
Conclusion
Clodronate combined with antioestrogens significantly increases bone mineral density in post-menopausal breast cancer patients.
Supporting Evidence
- Clodronate increased bone mineral density by 2.9% in the lumbar spine and 3.7% in the femoral neck at 2 years.
- Patients receiving only antioestrogens showed no significant changes in bone mineral density.
- Both tamoxifen and toremifene similarly prevented bone loss.
Takeaway
This study found that a medicine called clodronate helps women with breast cancer keep their bones strong when they take other treatments.
Methodology
121 post-menopausal breast cancer patients were randomized to receive either tamoxifen or toremifene with or without clodronate for 3 years, and bone mineral density was measured at baseline, 1 year, and 2 years.
Limitations
Data from 28 patients were excluded from analyses due to various reasons, including metastatic disease and protocol violations.
Participant Demographics
Post-menopausal women with early-stage breast cancer, aged around 61-62 years.
Statistical Information
P-Value
0.001 and 0.006
Confidence Interval
95%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website